Carba C Testing
The Revogene Carba C assay provides healthcare systems with a diagnostic solution to enable early detection and management of Carbapenem-Resistant Enterobacterales (CRE) from isolated colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa.
Catalog Number: 410500
Test Procedure
- Transfer colonies to obtain a standardized 0.5 MacFarland suspension.
- Vortex the 0.5 MacFarland suspension at maximum speed for 15 seconds.
- Using a micropipette, aspirate 15 µL of MacFarland suspension and dispense into the Sample Buffer Tube (SBT).
- Vortex the SBT at high speed for 15 seconds.
- Unseal the pouch containing the Revogene® Carba C PIE.
- Using the Disposable Transfer Tool (DTT), aspirate the Sample Buffer (SB) by squeezing the entire bulb until the liquid level is anywhere between the two lines on the DTT.
- Discharge the specimen completely into the Sample Loading Chamber of the PIE.
- Close the cap of the Sample Loading Chamber tightly.
- Start the test run by navigating to the
menu. Select Revogene® Carba C. Follow the onscreen instructions to load the patient test PIE. - Load the remaining patient tests. If less than eight (8) PIEs are being tested, load MOCK PIES in the carousel in the remaining positions.
- Scan the retention ring and place it on the carousel.
- Close the instrument lid with both hands and ensure the lid lock engages.
- Select
to initiate the test and walk away. - The lid opens when the run is complete.
- Remove all PIEs including MOCK PIES after the run.
- Tap the
icon to see test results.
Early detection is key for CRE infection prevention and control. The CDC recommends “detecting and protecting” through early identification of CRE carriers, followed by prevention of transmission through implementation of infection control precautions.
Support & Documents
Downloadable PDFs
FAQs
Revogene Carba C – 87150 x 5
1. https://www.cdc.gov/drugresistance/biggest_threats.html
2. https://www.cdc.gov/hai/organisms/cre/index.html
3. https://www.cdc.gov/hai/organisms/cre/cre-clinicianfaq.html
4. Neuner, E. & Gallagher J., 2017. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence. 8(4):440-452.
Get In Touch With A Specialist
